Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Covid19

In brief

This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.

Key facts

Study ID

NCT04445285

Run by

Jon Simmons

People needed

44

Starts

2020-04-28

Expected to finish

2022-02-28

Last updated by the study team

2021-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or Female age 18 or older
• On high flow oxygen =/> 6 liters nasal cannula (or)
• On mechanical ventilation
• Clinical diagnosis of COVID-19 \& positive PCR test (or)
• Clinical diagnosis of COVID-19 \& negative PCR test with clinical symptoms of COVID-19 and pathognomonic lesions on a chest CT scan

You may not qualify if…

• Known allergy to Pulmozyme
• Less than 18 years of age
• Grave condition with anticipated death within 48 hours; at the discretion of treating physician.
• Enrollment in another clinical trial receiving investigatory drugs

Where it is running

• University of South Alabama — Mobile, Alabama, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.